At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 289 enrolled
Drug / intervention
Cenicriviroc +1 moredrug
Likely dose
Cenicriviroc 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis
In Brief
A Phase 2 clinical trial evaluating Cenicriviroc and Placebo for Nonalcoholic Steatohepatitis. Completed, enrolled 289 participants across 91 sites in 10 countries.
Detailed Summary
The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNonalcoholic Steatohepatitis
CountriesAustralia, Belgium, France, Germany, Hong Kong, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartSep 2014
Primary CompletionJun 2016
Study CompletionJun 2017
TodayJul 2026
First PostedAug 15, 2014
Enrollment StartSep 18, 2014
Primary CompletionJun 30, 2016
Study CompletionJun 22, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.9 years ago
Interventions
Cenicrivirocdrug
CVC 150 mg, administered orally once daily and taken every morning with food.
Placebodrug
Placebo administered orally once daily and taken every morning with food.